Therapeutic options in neuromyelitis optica spectrum disorders

被引:27
作者
Kitley, Joanna [1 ]
Palace, Jackie [2 ]
机构
[1] Southampton Gen Hosp, Wessex Neurol Ctr, Dept Neurol, Southampton SO9 4XY, Hants, England
[2] Univ Oxford, Oxford Univ Hosp NHS Trust, Nuffield Dept Clin Neurosci, Level 3 West Wing, Oxford, England
关键词
NMOSD; treatment; AQP4-Ab; neuromyelitis optica spectrum disorders; aquaporin-4; NMO; Neuromyelitis optica; INTERLEUKIN-6 RECEPTOR BLOCKADE; PLASMA-EXCHANGE; INTRAVENOUS IMMUNOGLOBULIN; ANTI-AQUAPORIN-4; ANTIBODY; MYCOPHENOLATE-MOFETIL; DIAGNOSTIC-CRITERIA; POSITIVE PATIENTS; ACUTE RELAPSES; AQUAPORIN-4; NMO;
D O I
10.1586/14737175.2016.1150178
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Neuromyelitis optica is a relapsing inflammatory disorder of the central nervous system that manifests predominantly with attacks of optic neuritis and longitudinally extensive transverse myelitis; attacks are often severe. In contrast to multiple sclerosis, a secondary progressive phase is rare, and disability in neuromyelitis optica spectrum disorders is related to relapses. Thus, prompt and effective treatment of relapses, and early initiation of long-term immunosuppression to prevent subsequent attacks is required in order to prevent morbidity and mortality.
引用
收藏
页码:319 / 329
页数:11
相关论文
共 107 条
[1]   Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica A pilot study [J].
Araki, Manabu ;
Matsuoka, Takako ;
Miyamoto, Katsuichi ;
Kusunoki, Susumu ;
Okamoto, Tomoko ;
Murata, Miho ;
Miyake, Sachiko ;
Aranami, Toshimasa ;
Yamamura, Takashi .
NEUROLOGY, 2014, 82 (15) :1302-1306
[2]   Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 Therapy [J].
Ayzenberg, Ilya ;
Kleiter, Ingo ;
Schroeder, Alexandra ;
Hellwig, Kerstin ;
Chan, Andrew ;
Yamamura, Takashi ;
Gold, Ralf .
JAMA NEUROLOGY, 2013, 70 (03) :394-397
[3]   Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy [J].
Barnett, M. H. ;
Prineas, J. W. ;
Buckland, M. E. ;
Parratt, J. D. E. ;
Pollard, J. D. .
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (01) :108-112
[4]   Impact of rituximab on relapse rate and disability in neuromyelitis optica [J].
Bedi, Gurdesh S. ;
Brown, Andrew D. ;
Delgado, Sylvia R. ;
Usmani, Nida ;
Lam, Byron L. ;
Sheremata, William A. .
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (10) :1225-1230
[5]   A case of relapsing neuromyelitis optica treated with glatiramer acetate [J].
Bergamaschi, R ;
Uggetti, C ;
Tonietti, S ;
Egitto, MG ;
Cosi, V .
JOURNAL OF NEUROLOGY, 2003, 250 (03) :359-361
[6]  
Bichuetti DB, 2010, ARCH NEUROL-CHICAGO, V67, P1131, DOI 10.1001/archneurol.2010.203
[7]   Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder [J].
Bonnan, M. ;
Valentino, R. ;
Olindo, S. ;
Mehdaoui, H. ;
Smadja, D. ;
Cabre, P. .
MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (04) :487-492
[8]   Plasma Exchange in Severe Attacks of Neuromyelitis Optica [J].
Bonnan, Mickael ;
Cabre, Philippe .
MULTIPLE SCLEROSIS INTERNATIONAL, 2012, 2012
[9]   Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study [J].
Cabre, Philippe ;
Olindo, Stephane ;
Marignier, Romain ;
Jeannin, Severine ;
Merle, Harold ;
Smadja, Didier .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2013, 84 (05) :511-516
[10]   Pregnancy outcomes after maternal exposure to rituximab [J].
Chakravarty, Eliza F. ;
Murray, Elaine R. ;
Kelman, Ariella ;
Farmer, Pamela .
BLOOD, 2011, 117 (05) :1499-1506